Dr. Anitha. T.S.

Research Area

Dr. Anitha’s primary research interest is developing novel experimental and translational approaches to cancer therapeutics and ocular diseases, particularly on novel drug targeted signalling pathways and oxidative stress. She has done her doctoral research at Dept. of Animal Sciences, School of Life Sciences, Bharathidasan University (Tiruchirappalli, Tamil Nadu, India) on exploring the molecular basis of oxidative stress-induced cataractogenesis and the effect of traditional therapeutic intervention on cataract. She started her career as a Scientist at Central Inter-Disciplinary Research Facility (CIDRF), Sri Balaji Vidyapeeth (Deemed-to-be University), Puducherry in 2015. Being seven years of service at CIDRF, her research work focused on repurposing drugs for glioma treatment and determining their efficacy as well as synergistic effects when used in combination with the standard therapeutic regime. She has received extramural funding from institutional as well as national agencies such as ICMR, DSTE (Gov. of Puducherry). She has published several research papers in peer-reviewed journals including Life Sciences, Cellular Signaling, Current Molecular Pharmacology, and Medical Oncology, among others. In addition, she has several national and international collaborations and engage herself as a consultant to various R&D laboratories.
Dr. Anitha T.S joined Pondicherry University as an Assistant professor in 2022 and is currently involved in teaching as well as research work. Her research goal is to turn basic science -backed hypotheses into molecular medicine for cancer diseases, and contribute to improving the survival of patients afflicted with the dreadful disease.

Research Guidance
0 years
Teaching Experience

Notable Publications

Crosstalk between PI3K/AKT/mTOR and WNT/β-Catenin signaling in GBM - Could combination therapy checkmate the collusion?

Integration of synthetic and natural derivatives revives the therapeutic potential of temozolomide against glioma- an in vitro and in vivo perspective.

Will CRISPR-Cas9 Have Cards to Play Against Cancer? An Update on its Applications.

Can artificial intelligence overtake human intelligence on the bumpy road towards glioma therapy?

Wnt/β-catenin Antagonists: Exploring New Avenues to Trigger Old Drugs in Alleviating Glioblastoma Multiforme.

News & Events

No News to display.
No Events to display.
Translate »